Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：232

作者：

Verheijen, Remy B. ^{[1
]}

Yu, Huixin ^{[1
]}

Schellens, Jan H. M. ^{[2
,3
]}

Beijnen, Jos H. ^{[1
,3
]}

Steeghs, Neeltje ^{[2
]}

Huitema, Alwin D. R. ^{[1
,4
]}

机构：

[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands

[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands

[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands

[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期

关键词：

CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;

D O I：

10.1002/cpt.787

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

引用

页码：765 / 776

页数：12

共 50 条

[41] Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions
Lewis, Russell E.
Andes, David R.
CURRENT OPINION IN INFECTIOUS DISEASES, 2021, 34 (04) : 288 - 296
[42] The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology
Touma, Josephine A.
McLachlan, Andrew J.
Gross, Annette S.
TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1558 - +
[43] The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic MyeloidLeukemiaandMetastatic or Unresectable Gastrointestinal Stromal Tumors
Teng, Jennifer F. T.
Mabasa, Vincent H.
Ensom, Mary H. H.
THERAPEUTIC DRUG MONITORING, 2012, 34 (01) : 85 - 97
[44] Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?
Bastida, Carla
Ruiz, Virginia
Pascal, Mariona
Yague, Jordi
Sanmarti, Raimon
Soy, Dolors
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) : 962 - 975
[45] Therapeutic drug monitoring of biologics in psoriasis
Liau, MeiQi May
Oon, Hazel H.
BIOLOGICS-TARGETS & THERAPY, 2019, 13 : 127 - 132
[46] Therapeutic drug monitoring of antifungal agents
Heinz, Werner J.
Klinker, Hartwig
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2012, 36 (02): : 99 - 109
[47] Therapeutic Drug Monitoring of Lamotrigine.
Bentue-Ferrer, Daniele
Tribut, Olivier
Verdier, Marie-Clemence
THERAPIE, 2010, 65 (01): : 39 - 46
[48] Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature
Bertolaso, Pauline
Gross-Goupil, Marine
Molimard, Mathieu
Cochin, Valerie
Ravaud, Alain
Daste, Amaury
CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : E885 - E887
[49] Towards point of care systems for the therapeutic drug monitoring of imatinib
Pearce, Charles M.
Resmini, Marina
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2020, 412 (24) : 5925 - 5933
[50] Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
Groenland, S. L.
van Eerden, R. A. G.
Westerdijk, K.
Meertens, M.
Koolen, S. L. W.
Moes, D. J. A. R.
de Vries, N.
Rosing, H.
Otten, H.
Vulink, A. J. E.
Desar, I. M. E.
Imholz, A. L. T.
Gelderblom, H.
van Erp, N. P.
Beijnen, J. H.
Mathijssen, R. H. J.
Huitema, A. D. R.
Steeghs, N.
Dutch Pharmacology Oncology Grp DPOG
ANNALS OF ONCOLOGY, 2022, 33 (10) : 1071 - 1082

← 1 2 3 4 5 →